Cargando…
Reply to Kobayashi et al.: Too Premature to Deny the Potential of Thrombomodulin Alfa in Idiopathic Pulmonary Fibrosis
Autores principales: | Kondoh, Yasuhiro, Azuma, Arata, Tagawa, Jun, Yamamori, Natsuki, Homma, Sakae |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Thoracic Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7258633/ https://www.ncbi.nlm.nih.gov/pubmed/32150449 http://dx.doi.org/10.1164/rccm.202002-0398LE |
Ejemplares similares
-
Too Premature to Deny the Potential of Thrombomodulin Alfa in Idiopathic Pulmonary Fibrosis
por: Kobayashi, Tetsu, et al.
Publicado: (2020) -
Reply to Horita and Takeshi: Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial
por: Kondoh, Yasuhiro, et al.
Publicado: (2020) -
Therapeutic Role of Recombinant Human Soluble Thrombomodulin for Acute Exacerbation of Idiopathic Pulmonary Fibrosis
por: Isshiki, Takuma, et al.
Publicado: (2019) -
Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan
por: Ogura, Takashi, et al.
Publicado: (2023) -
Design of phase 2 study of TAS-115, a novel oral multi-kinase inhibitor, in patients with idiopathic pulmonary fibrosis
por: Nishioka, Yasuhiko, et al.
Publicado: (2021)